Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vertex ROCK inhibitor compound 22
- Development stage
- Preclinical
- Lead developer
- Vertex
- Modality
- Small Molecules
- Administration
- Ophthalmic, Oral
01
Overview
Vertex ROCK inhibitor compound 22 is a potent, small molecule inhibitor of Rho-associated coiled-coil-containing protein kinases 1 and 2 (ROCK1 and ROCK2), originally identified by Vertex Pharmaceuticals during structure-activity relationship (SAR) studies. The compound functions by binding to the ATP-binding pocket of the ROCK catalytic domain, thereby preventing the phosphorylation of downstream substrates involved in cytoskeletal regulation. By inhibiting ROCK signaling, the molecule influences critical cellular functions such as actin filament organization, cell migration, and smooth muscle contraction. Due to these effects, it has been investigated for therapeutic potential in treating glaucoma (by enhancing aqueous humor outflow), cardiovascular diseases (through vasodilation and reduction of vascular resistance), and cancer (by hindering tumor cell invasion and metastasis).
- Other names
- Vertex compound 22
02
Targets
ROCK1 (Rho-associated coiled-coil containing protein kinase 1)
Beyond the preview
Go deeper on Vertex ROCK inhibitor compound 22.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vertex ROCK inhibitor compound 22.